| 영문 | rheumatoid factor | 한글 | 류마티스 인자 |
|---|---|---|---|
| 설명 | IgG의 Fc부위에 있는 항원결정인자에 대한 항체로서 전형적인 또는 확실한 류마티스관절염(rheumatoid arthritis) 환자의 80%에서 발견된다. 류마티스 인자는 IgM, IgG, IgA중 하나가 될 수 있으나 주로 IgM이다. 소아류마티스관절염(juvenile rheumatoid arthritis: 소아기에 발생하는 류마티스관절염)을 비롯한, 다른 결합조직병이나 감염병에도 나타날 수 있다 |
||
| 영문 | growth factor | 한글 | 성장인자 |
|---|---|---|---|
| 설명 | 세포의 분화 및 성장에 관여하는 단백질. 성장인자는 정상 세포주기에 필수적이기 때문에 동물의 생명에 중대한 요소가 된다. 무엇보다도 성장인자는 태아의 발육을 조정하고 조직의 유지 및 보수에 중대한 역할을 하며, 혈구의 생성을 자극한다. 또한 암의 진행과정에도 관여한다. |
||
| 영문 | risk factor | 한글 | 위험인자 |
|---|---|---|---|
| 설명 | 국제방사선방호위원회(ICRP)가 1977년 권고에서 방사선방호의 목적으로 채택한 지수로, 단위선량(1 Sv)당 확률적 영향의 발생확률을 추정하여 나타낸 것이다. 생식선 선량에 대한 유전적영향의 발생률(4×10－3/Sv)이나 적색골수선량에 대한 백혈병 발생률(2×10－3/Sv)등 외에 뼈, 허파, 갑상샘, 젖샘, 기타 조직의 위험지수를 측정하여, 확률적 영향의 전신에 있어서 치사위험지수의 합계를 16.5×10－3/Sv로 하였다. 그후 ICRP는 1990년 권고에서 대상이 되는 조직과 장기를 추가하고, 수치 개정을 하면서 명칭도 각목적확률지수라고하였다. 이 권고에 의하면, 치사적 확률적 영향의 확률지수의 합계는, 일반인에 있어 60.0×10－3/Sv이다. |
||
| CF | calcaneal fibular [ligament]; calcium leucovorin; calf blood flow; calibration factor; cancer-free; ... |
|---|---|
| EF | ectopic focus; edema factor; ejection fraction; elastic fibril; electric field; elongation factor; e... |
| PF | pair feeding; peak flow; perfusion fluid; pericardial fluid; periosteal fibroblast; peritoneal fluid... |
| EPF | early pregnancy factor; endocarditis parietalis fibroplastica; endothelial proliferating factor; est... |
| EDRF | Endothelium Derived Relaxing Factor |
| EDRF | Endothelial-derived relaxing factor |
|---|---|
| EDRF | Endothelium Dependent Relaxing Factor |
| EDRF | Endothelium Derived Relaxing Factor |
| EDRF-NO | Endothelium-derived relaxing factor-nitric oxide |
| VEGF/VPF | Vascular endothelial growth factor/ vascular permeability factor |
IGF-II : insulin like growth factor-II의 약자. 많은 장기와 조직에 작용하여 단백 합성과 DNA, RNA의 합성을 증가시켜 세포의 수와 양을 증가
| endothelial relaxing factor | A molecule functioning as a neurotransmitter and produced by activated macrophages. It is capable of killing tumour cells, parasites, and intracellular bacteria. (05 Mar 2000) |
|---|
| endothelium-derived relaxing factor | A labile humoral agent released by the vascular endothelium that mediates the relaxation induced by some vasodilators such as acetylcholine and bradykinin. Edrf also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. These actions are believed to be mediated through stimulation of guanylate cyclase and the consequent elevation of cyclic guanosine 3',5'-monophosphate. Edrf is thought to be nitric oxide or a ready source of it. The factor is believed to be unstable and acts only locally in vivo. (12 Dec 1998) |
|---|---|
| uterine relaxing factor | <protein> Polypeptide hormone produced by corpus luteum and found in the blood of pregnant animals. Acts, as its name suggests, to cause muscle relaxation during parturition. Human relaxin has an A chain of 24 amino acids and a B chain of 29. Has structural similarity to insulin. (18 Nov 1997) |
| vascular endothelial growth factor | A growth factor that is responsible for the growth of blood vessels. (12 Dec 1998) |
| relaxing enzyme | <biochemistry> Any of several enzymes, such ashelicase, that unwind DNA prior to its replication. (09 Oct 1997) |
| platelet endothelial cell activated protease | <enzyme> Degrades casein and fibrinogen; secreted by endothelial cells and activated in the extracellular medium by platelets; not inhibited by serine protease inhibitors, metalloproteinase inhibitors, or cystein protease inhibitors; pH optimum 7.5 Registry number: EC 3.4.99.- Synonym: pecap (26 Jun 1999) |
| corneal endothelial polymorphism | A greater than normal variation in the shape of the cells. (05 Mar 2000) |
| high endothelial postcapillary venules | Venule's in the lymph nodes, tonsils, and Peyer's patches that have a high-walled endothelium through which blood lymphocytes migrate into the lymphatic parenchyma. (05 Mar 2000) |
| intravascular papillary endothelial hyperplasia | A benign florid papillary endothelial proliferation within the veins of the skin or subcutis, less often in visceral blood vessels. Synonym: Masson's pseudoangiosarcoma. (05 Mar 2000) |
| iridocorneal endothelial syndrome | <syndrome> Syndrome of glaucoma, iris atrophy, decreased corneal endothelium, anterior peripheral synechia, and multiple iris nodules. Synonym: Cogan-Reese syndrome, iris-nevus syndrome. (05 Mar 2000) |
| endothelial | Pertaining to or made up of endothelium. (16 Dec 1997) |
| endothelial cell | A thin, flattened cell, a layer of them lines the inside surfaces of body cavities, blood vessels, and lymph vessels, making up the endothelium. (09 Oct 1997) |
| endothelial cyst | A serous cyst whose sac is lined with endothelium. (05 Mar 2000) |
| endothelial dystrophy of cornea | Spontaneous loss of corneal endothelium leading to oedema of the corneal stroma and epithelium. (05 Mar 2000) |
| endothelial growth factors | These growth factors are soluble mitogens secreted by a variety of organs. The factors are a mixture of two single chain polypeptides which have affinity to heparin. Their molecular weight are organ and species dependent. They have mitogenic and chemotactic effects and can stimulate endothelial cells to grow and synthesise DNA. The factors are related to both the basic and acidic fibroblast growth factors but have different amino acid sequences. (12 Dec 1998) |
| endothelial leukocyte | Old term for a monocyte, a type of leukocyte thought to be derived from reticuloendothelial tissue. (05 Mar 2000) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|